New vaccine prevents CMV infection and disease in mice

Jun 22, 2007

Researchers at the University of California, San Diego (UCSD) Skaggs School of Pharmacy and Pharmaceutical Sciences have patented a strategy for developing a human vaccine to prevent against Human Cytomegalovirus (hCMV) infection and disease.

CMV, a type of herpes virus, is the leading viral cause of birth defects and a serious problem in patients with compromised immune systems. The body’s natural immunity doesn’t protect against infection by the virus, estimated to be present in 50 to 75 percent of all adults.

“Until now, scientists haven’t been able to develop a vaccine to protect against CMV,” said Deborah H. Spector, Ph.D., UCSD Professor of Cellular and Molecular Medicine and faculty member of the Skaggs School of Pharmacy and Pharmaceutical Sciences. “Using a two-pronged approach, we successfully created and tested a vaccine in a mouse model with CMV that shows enormous promise for re-directing the body’s immune system, enabling it to fight the virus.”

The mouse vaccine generates an immune response that protects against both infection and development of disease when the virus is present by completely disarming the virus’s ability to replicate and establish a persistent infection. The work is currently online in advance of publication in the July issue of Journal of Virology.

“Our approach generates an immune response that is different from the normal response to the virus, and we hope to have found an ‘Achilles’ heel’ in the defenses that the virus uses to evade the immune system,” said Spector. “The virus has evolved to persist in the host by evading the immune responses either by hiding or by misdirecting the host’s immune responses. We found a way to teach the host immune system to not be tricked by the virus.” She added that the next step is to apply this strategy to create a vaccine for use in humans.

CMV is a virus that, while carried by the majority of adults in the United States, can remain dormant for years, if not the lifetime, of a healthy individual. However, two percent of all children are born with the virus passed on by the mother in utero, and 15 percent of those children will show symptoms such as hearing loss, mental retardation, motor or learning disabilities. Because the host’s natural immune system can protect from the disease but can’t rid the body of the virus, people remain infected and can become re-infected or infect others through saliva.

“Children in day care settings, for example, or adults who are sexually active, can pass along the virus,” explained Spector. “It becomes a serious problem in developing infants during the pregnancy or in those whose immune system is compromised, such as AIDS or transplant patients.”

When a persistent virus such as CMV infects an individual, it disarms the host immune system in two ways – by hiding or masking the proteins that would normally provoke an immune response, or by fooling the immune system into mounting a response that doesn’t work to eradicate the virus.

“We needed a way to make the host defense system sit up and take notice,” said Christopher S. Morello, Ph.D., first author of the study.

To do this, the researchers devised a vaccine with a one-two punch that combines a DNA immunization that targets T-cells to essential genes required for CMV replication, with a killed virus that prompts the body’s B-cells to generate an antibody response.

The vaccine contains the DNA of two essential genes that are essential for replication of the virus. These genes – which are also found in other herpes viruses such as chicken pox or herpes simplex – have the same or very similar sequence, structure and function whether in human or mouse viruses, and present a novel target for the host’s T-cells to muster forces and attack the virus. Secondly, the vaccine also contains a “boost” from an inactivated virus, which generates an antibody response. Neither approach alone would give complete protection.

“In mice, the vaccine not only fought the disease, but prevented the infection from being established in the first place,” Morello said.

Researchers at UCSD hope to begin pre-clinical work on development of a human vaccine. If successful, an FDA-approved, commercially licensed hCMV vaccine could be administered to specific at-risk populations, such as females prior to child-bearing years, day care providers, organ transplant recipients, or as part of regular childhood immunizations.

“This approach may also be valid for a number of diseases associated with persistent or latent infections, including all types of herpes-associated diseases, AIDS, or hepatitis,” said Spector. These viruses persist because immune responses generated by the viral infection are not able to eradicate the virus.

Source: University of California - San Diego

Explore further: A new way to diagnose malaria, using magnetic fields

add to favorites email to friend print save as pdf

Related Stories

Caterpillar comet poses for pictures en route to Mars

10 minutes ago

Now that's pure gorgeous. As Comet C/2013 A1 Siding Spring sidles towards its October 19th encounter with Mars, it's passing a trio of sumptuous deep sky objects near the south celestial pole this week. ...

Hoisting a telescope with helium

20 minutes ago

Many a child has forgotten to hold tight to the string of a helium balloon only to have it escape and rise until it disappeared in the glare of the sun. Helium balloons want to rise, but launching a balloon ...

The chemistry of beer and coffee

21 minutes ago

University of Alabama at Birmingham professor Tracy Hamilton, Ph.D., is applying his chemistry expertise to two popular beverages: beer and coffee.

Recommended for you

Researchers try to make sure herpes does not find a home

59 minutes ago

The immune system is great at making sure infections such as the herpes virus do not repeatedly infect a person, a condition known as a superinfection. Yet how the immune system combats superinfection is ...

A new way to diagnose malaria, using magnetic fields

19 hours ago

Over the past several decades, malaria diagnosis has changed very little. After taking a blood sample from a patient, a technician smears the blood across a glass slide, stains it with a special dye, and ...

How Alzheimer's peptides shut down cellular powerhouses

Aug 29, 2014

The failing in the work of nerve cells: An international team of researchers led by Prof. Dr. Chris Meisinger from the Institute of Biochemistry and Molecular Biology of the University of Freiburg has discovered ...

User comments : 0